NyQuil D behind the counter
This article was originally published in The Tan Sheet
Executive Summary
NyQuil Dis launching with the same pseudoephedrine-containing formula as the original Nyquil, but sold behind retail counters, Procter & Gamble announces Oct. 1. Part of the Vicks cough, cold and flu line, the 10 oz. formula carries an SRP of $6.32. P&G removed PSE from Vicks products due to illicit use of the ingredient and because the Combat Meth Act prohibits OTC sales of PSE products (1"The Tan Sheet" March 6, 2006, p. 5)...
You may also be interested in...
Pseudoephedrine Will Be Behind The Counter Across The Country By October
Retailers will have to be prepared to enforce monthly gram purchase limits on pseudoephedrine products by mid-April, once meth control provisions of the Patriot Act reauthorization bill go into effect
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.